Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- PennyStockEarnings Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is On: Repros Therapeutics Inc (NASDAQ:RPRX), Illumina, Inc. (NASDAQ:ILMN), Aastrom Biosciences Inc (NASDAQ:ASTM), Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)
Repros Therapeutics Inc (NASDAQ:RPRX) climbed +0.53% and closed at $28.25 in the last trading session with the overall traded volume of 1.69 million shares, more versus the average volume of 890,454 shares. Its 52 weeks high price was $28.64 and suffered lowest price of $8.42 in the same period.
It has market cap of $649.89 million while its total outstanding shares are 23.00 million. Its stock’s 3 months performance stands at +38.45%. Repros Therapeutics Inc., a development stage biopharmaceutical company, engages in the development of new drugs to treat hormonal and reproductive system disorders.
For How Long RPRX will Fight for Profitability? Read This Trend Analysis report
Illumina, Inc. (NASDAQ:ILMN) declined -0.89% with the closing price of $80.94. The overall volume in the last trading session was 1.31 million shares. Its fifty two week range was $44.78-$85.81. The total market capitalization remained $10.07 billion.
The stock gained +47.84% in this year and reported the loss of -4.27% in the last 5 days. In its share capital, the company has 124.38 million outstanding shares. Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa.
Will ILMN Get Buyers Even After The Recent Rally? Find Out Here
Aastrom Biosciences Inc (NASDAQ:ASTM) decreased -3.01% to close at $0.290 in the last trading session and its total traded volume was 1.27 million shares, beating the average volume of 2.00 million. The company has market cap of $21.94 million.
The stock has negative year-to-date performance of -77.17% while its quarterly performance remained -42.82%. Aastrom Biosciences, Inc., a development stage company, engages in the development of patient-specific, cell products for use in the treatment of severe, chronic ischemic cardiovascular diseases.
Has ASTM Found The Bottom and Ready To Move Up? Find Out Here
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) declined -10.62% to closed at $3.45 and its overall volume in the last trading session was 1.26 million shares, beating the average volume of 948,741. It has market cap of $140.56 million while its total outstanding shares are 40.74 million.
The stock gained +65.07% in this year and reported the loss of -23.33% in the last 5 days. Its 3 months performance stands at +57.53%. Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of neurological disorders in Australia.
Why Should Investors Buy PRAN After the Recent Fall? Just Go Here and Find Out
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)